ABSTRACT

There are marked differences in the pathogenesis of the lung and liver disorders in alpha 1-antitrypsin (alAT) deficiency. In this regard, it is not surprising that the therapeutic strategies for these different manifestations of a 1 AT deficiency should also differ markedly.